Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in prometaphase, followed by a surge in apoptosis. AAPK-25 targets Aurora-A/-B/-C with Kd values ranging from 23-289 nM, a
ターゲット&IC50 | PI3K:7.11 μM (kd), PLK2:272 nM (kd), Aurora B:78 nM (kd), PLK3:456 nM (kd), Aurora A:23 nM (kd), ERK:5.32 μM (kd), Aurora C:289 nM (kd), CDK:8.02 μM , PLK1:55 nM (kd) |
分子量 | 442.32 |
分子式 | C21H13Cl2N3O2S |
CAS No. | 2247919-28-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (113.04 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AAPK-25 2247919-28-2 Apoptosis Cell Cycle/Checkpoint Chromatin/Epigenetic PLK Aurora Kinase AAPK 25 inhibit Polo-like Kinase (PLK) AAPK25 Inhibitor inhibitor